reports
Mithra updates on offers received in the context of its monetization p...
Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023 Mithra has received binding offers for selected assets, including Estetra SRL, as part of its monetization process. As it stands, the aggregate amount of these offers is insufficient to ensure full repayment of all creditors of Mithra, and, therefore, the offers do not allow to create value for Mithra’s shareholders at the present time.Mithra has requested the suspension of trading of its shares on Euronext Brussels pending continuing negotiations with offering parties.Mithra postpones...
- Lynn Hautekeete
Qrf City Retail Catalysts not translated in share price reaction
We update our model after the 1Q24 results and take into account the exit from the Dutch market, JV closing and non-strategic asset sales announced in 1Q24. We believe the stock price did not react enough to the positive catalyst of the Dutch sales and JV closing at 15.13% IRR. Hence, we repeat our BUY recommendation and EUR 13.0 TP. Standing asset valuations increased with 1.3% in 1Q24 signalling the revival of retail real estate. This is also reflected in the record high occupancy rate at 99....
Mithra secures court protection measures to advance monetization proce...
Mithra secures court protection measures to advance monetization process Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization.Approval of Judicial Reorganization Proceedings for Novalon SA, facilitating an amicable agreement with some creditors and restructuring the debt of Mithra's complex therapeutics business.Mithra Advances Monetization Process with Court Protection Measures, marking significant milestones in the company's commitment to maximizing ...
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
Inventiva announces filing of its 2023 Universal Registration Document...
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registra...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), ou NASH, et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enregistrement...
- Jacob Mekhael
Inventiva FY23 conference call feedback
In this note we provide a summary of the feedback from Inventiva's FY23 conference call. The company's CEO provided an overview of Inventiva's progress in 2023 and early 2024. This was followed by Q&A which largely focussed on the resumption of recruitment in the phase 3 (NATiV3) trial with lanifibranor in MASH, strength of the lanifibranor dataset vs. competitors, as well as partnering and funding options to reach NATiV3 topline readout expected in 1H26. Read our morning note on Inventiva's FY2...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva FIRST LOOK: Uneventful FY23 results, NATiV3 LPFV still by 1H...
Inventiva reported FY23 results with a cash position of € 26.9m (YE22: € 86.7m), which together with the 2nd EIB tranche of € 25m announced in January 2024, provides the company with a cash runway until the beginning of 3Q24. This is sufficient to fund Inventiva beyond the NATiV3 last patient first visit (albeit just about), expected by 1H24 – we view this as an important milestone as it would provide timeline certainty by pinning the topline readout to 1H26. We point to the improved sentiment a...
Inventiva announces the nomination of Andre Turenne as Director
Inventiva announces the nomination of Andre Turenne as Director Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne’s appointment wil...
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrat...
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur Daix (France), Long Island City (New York, États-Unis), le 28 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), ou NASH, et d’autres maladies avec un besoin médical non satisfait, a annoncé aujourd'hui la nomination d'Andre Turenne à son Conseil d'Administration. La nomination de M. Ture...
Inventiva publie ses résultats annuels 2023
Inventiva publie ses résultats annuels 2023 Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022Trésorerie et équivalents de trésorerie de 26,9 millions d’euros, dépôt à court terme de 0,01 million d’euros1 et dépôt à long-terme de 9,0 millions d’euros2 au 31 décembre 2023, contre respectivement 86,7 millions d’euros, 1,0 million d’euros et 0,7 million d’euros au 31 décembre 2022 En septembre 2023, Inventiva a conclu un accord de licence exclusif avec Hepalys pour développer et commercialiser lanifibranor au Japon et ...
Inventiva reports its 2023 full-year results
Inventiva reports its 2023 full-year results Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In September 2023, Inventiva entered into an exclusive licensing agreement with Hepalys to develop and commercialize lanifibranor in Japan and South Korea In January 2024, Inventiva received the second tranche...
- Lynn Hautekeete
- Wim Lewi
Real Asset Conference Soundbites 19-20 March 2024
This note gathers feedback from the group meetings and the break-out sessions. In total 23 companies presented in group meetings and/or break-out sessions. More than 100 guests found their way to the venue and some more followed virtual meetings. Physical attendance is clearly on the rise after the COVID disruption. Investing remains a people's business. The 4 break-out sessions made for informative additions to the C-level meetings and a nice platform for discussion. Tuesday morning concentrate...
LEAS LEASINVEST REAL ESTATE SCA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
CTPNV CTP NV
SHUR SHURGARD SELF STORAGE LIMITED
Inventiva announces the schedule of publication and presentation of it...
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Compan...
Inventiva annonce la date de publication et de présentation de ses rés...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), ou NASH, et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui que son équipe de direction présentera les résultats financiers 2023 de l...
- Jacob Mekhael
- Sharad Kumar S.P
- Thibault Leneeuw
- Wim Hoste
- Jacob Mekhael
Inventiva LEGEND data and prescriber survey highlight lani's potential...
Following the announcement of positive phase 2 (LEGEND) results with lanifibranor + empagliflozin in MASH and T2D, hitting on the primary and multiple secondary endpoints, Inventiva's stock traded down approx. -11%. We believe this response is unjustified given that the results showcase lanifibranor's potential as a combination therapy, further boosting the candidate's positioning in MASH. In addition, Inventiva presented results from payer and prescriber surveys, which we see as further support...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
- Jacob Mekhael
Inventiva FIRST LOOK: Phase 2 (LEGEND) trial of lani combo in MASH and...
Inventiva reported positive topline data from the phase 2 (LEGEND) trial of lanifibranor + empagliflozin in MASH and T2D. In addition to hitting on the primary endpoint (HbA1c), we note the stabilisation of weight as well as improvements in secondary outcomes (e.g. liver enzymes and fibrosis markers). In our view, the results boost lanifibranor's positioning in MASH, demonstrating its potential as a combination therapy, which is important given that combinations will likely be required to addres...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.